Leveraging Real-World Evidence in Sequencing Decisions for mCRC

Panelists explain that in the absence of head-to-head trial data, real-world evidence (RWE) becomes crucial in guiding sequencing decisions between agents such as trifluridine/tipiracil, fruquintinib, and regorafenib.

They highlight how RWE provides insights into treatment outcomes across broader and more diverse patient populations than those typically seen in clinical trials.

This information allows clinicians to refine sequencing strategies, especially when balancing efficacy and tolerability for patients in later-line settings.